The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer's disease.
Persons aged between 50 – 89 who have been diagnosed with mild to moderate Alzheimer's disease.
After the initial screening period, subject with receive an infusion of IGIV, 10% or placebo, every other week, for 18 months. Subjects will periodically receive brain MRI’s, physicals, lab work, and cognitive testing.
Please contact Barbara Lokaitis, CCRP, at 217.545.9737 or email email@example.com
Tom Ala, MD